Another limitation is that only clinical criteria without AD specific molecular imaging (Aβ-PET) or biofluid (CSF, plasma, Aβ/p-tau) biomarkers were used as the gold standard for the etiological diagnoses. Here, MAPT is linked to Alzheimer disease.